New Zealand Faces 82% Surge in Gynaecological Cancers by 2045, Urgent Call for Collective Action from NZMJ Study

A groundbreaking study published in the New Zealand Medical Journal (NZMJ) on 13 March 2026 has projected a dramatic 82% increase in annual gynaecological cancer cases in Aotearoa New Zealand by 2045, rising from 1,375 cases in 2020–2022 to 2,497 (95% uncertainty interval 2,263–2,774). Led by epidemiologist Michael Walsh from Health New Zealand – Te Whatu Ora, the research combines cancer registry data from 2001–2022 with population projections to forecast national and regional trends, highlighting stark ethnic disparities and an opportunity for proactive intervention. This projection model underscores the growing burden on healthcare services, particularly for uterine cancer, and emphasises the need for enhanced prevention, screening, and equitable service planning.

Gynaecological cancers encompass malignancies of the female reproductive system, including cervical, ovarian (including fallopian tube), uterine (endometrial), and others like vulvar and vaginal cancers. In New Zealand, these cancers already claim significant lives, with uterine cancer incidence rising sharply due to factors like excess body weight and diabetes, disproportionately affecting Māori and Pacific women. The study's authors – including gynaecologists Bryony Simcock and Sathana Ponnampalam – warn that without targeted action, the healthcare system will face unprecedented pressure, especially in regions with high Pacific populations.

Methodology Behind the Projections: Robust Age-Period-Cohort Modelling

The study employs sophisticated age-period-cohort (APC) Poisson regression models to project incidence rates. Data from New Zealand's national cancer registry (ICD-10 codes: cervical C53, uterine C54–C55, ovarian/fallopian C56/C57.0, others C51–C52/C57 excl. C57.0/C58) spanning 2001–2022 were stratified by 5-year age groups, prioritised ethnicity (Māori, Pacific, Asian, European/Other), and four Te Whatu Ora regions: Northern, Te Manawa Taki, Central, Te Waipounamu. Population denominators came from Statistics New Zealand, with recent trends weighted (power 1.5) and uncertainty quantified via 1,000 bootstraps (95% UI).

Age-standardised rates (ASRs) use the WHO 2001 standard. Adjustments addressed coding changes, such as combining ovarian and fallopian cancers reflecting emerging evidence on fallopian tube origins. Projections extend beyond 2022, accounting for escalating population uncertainty (SD 0.005–0.025). This method builds on prior University of Otago work on broader cancer projections to 2044, providing sub-national granularity essential for resource allocation.

National Projections: Uterine Cancer Drives the Surge

Nationally, the age-standardised incidence rate (ASR) for all gynaecological cancers is set to climb 21%, from 36.6 per 100,000 (95% CI 35.5–37.8) to 44.2 (95% UI 38.9–50.3) by 2045. Uterine cancer dominates the increase, more than doubling from 717 to 1,506 annual cases (ASR 18.6 to 27.1), accounting for over half the total burden by 2045. In contrast, cervical and ovarian cancers show modest case rises (~5%) but declining ASRs (cervical 5.1 to 4.7; ovarian 6.7 to 5.8 per 100,000), 'other' cancers surging 184% to 460 cases (ASR 5.1 to 6.4).

• Cervical: 169 to 178 cases; unlikely to meet WHO elimination target (<4/100,000).
• Ovarian/Fallopian: 327 to 342 cases; cautious interpretation due to reclassifications.
• Uterine: Primary driver, linked to obesity/diabetes epidemics.
• Other (vulvar/vaginal/etc.): Sharpest proportional rise.

These trends mirror global patterns but are amplified by New Zealand's ageing population and ethnic shifts.Explore research careers in oncology at New Zealand universities.

Ethnic Disparities: Alarming Increases for Māori and Pacific Women

Equity gaps widen dramatically. Māori cases rise 132% (214 to 497, ASR 50.7 to 63.6), Pacific 137% (165 to 391, ASR 97.3 to 122.3). Pacific women face the highest ASRs, especially uterine (74.3 to 97.5 per 100,000), driven by excess body weight prevalence (over 70% in Pacific adults vs. 32% European). 'Other' cancers see extreme rises (Māori +291%, Pacific +675%). Asian totals +223% (131 to 423), European/Other more moderate. Te Aho o Te Kahu's 2025 report confirms Pacific uterine incidence 5.6x European/Other, Māori over 2x, with modifiable risks preventing up to 50% cancers.

Historical inequities persist: Māori/Pacific lower screening, later diagnoses. University of Auckland and Otago research highlights cultural barriers, advocating self-sampling HPV tests boosting Māori/Pacific uptake.

Regional Variations: Northern Region Bears Heaviest Burden

Projections reveal stark regional differences. Northern Region sees largest absolute (+506 cases, 527 to 1,033; +96%) and uterine rise (296 to 662). Te Waipounamu +67% (325 to 544), Central +67% (256 to 427), Te Manawa Taki +86% (267 to 496). Northern's growth ties to Pacific demographics; all regions see uterine doublings, 'other' cancers +200–300%.

These inform localised planning, e.g. Northern bolstering gynae oncology via Auckland university-trained specialists.

Drivers of the Increase: Demographics, Risks, and Global Context

Population growth (+25% by 2045), ageing (more postmenopausal women), ethnic shifts (Pacific growth) fuel rises. Modifiable risks dominate: excess weight links ~40% Māori, >50% Pacific cases; diabetes 2–3x risk. Global trends align (1.47M cases 2022, rising), but NZ's inequities exceed. Te Aho notes 50% cancers preventable via lifestyle, HPV vaccination.

Current Landscape: Incidence, Mortality, and Survival Stats

2025 State of Cancer: Uterine rising fastest gynaecological type; cervical mortality down (37 deaths 2022). 5-year survival overall 67.6% (up from 58% 1990s), but Māori/Pacific lag (e.g. breast proxy ~2x mortality). Screening: Cervical 72.7% (Māori 57–64%, Pacific 55–61% recent gains via self-test); targets unmet.Te Aho o Te Kahu State of Cancer 2025 Ovarian ~306/year, 6th leading female cancer death.

• Coverage gaps exacerbate late diagnoses (85% cervical cases unscreened).
• Workforce: Gynaecological oncologists short (3/million benchmark unmet).

Service Implications: Strain on Gynae Oncology and Need for Capacity Building

82% case rise demands doubled specialists, theatres, chemo/radiotherapy slots. Northern/Te Waipounamu hardest hit. Universities like Otago (Gynaecological Cancer Research Group) and Auckland train future workforce; research microbiota/biomarkers vital. ANZGOG trials enhance outcomes. Check higher-ed-jobs for oncology roles.

Pathways to Prevention: Screening, Vaccination, and Lifestyle Interventions

Authors propose 'spectrum of action': community awareness (abnormal bleeding), 90% HPV vax by 15, 70% screening 35/45, 90% treatment. Self-testing lifts Māori/Pacific participation. Obesity/diabetes programs key; culturally safe navigation essential. Universities pioneer equity research.

The Role of Universities in Tackling Gynaecological Cancers

New Zealand universities drive innovation: Otago's projections models, Auckland's HPV research, Cochrane NZ reviews. Med schools train gynae oncologists amid shortages. PhD/MBChB programs integrate equity; explore university jobs in NZ health research. Collaborations with Te Whatu Ora amplify impact.

Photo by Himanshu Pandey on Unsplash

Future Outlook: Collective Action for Equity and Elimination

By 2045, without change, inequities widen, services overload. Optimism via prevention: cervical elimination viable with vax/screening boosts; uterine stabilise via risks. Authors urge holistic, anti-stigma approaches, research investment, Māori/Pacific-led services. AcademicJobs.com supports careers advancing this: Rate My Professor, Higher Ed Jobs, Career Advice. Act now for healthier Aotearoa.